Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.

@article{ErelAkbaba2019RadiationInducedTN,
  title={Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.},
  author={G{\"u}lşah Erel-Akbaba and L. Carvalho and Tian Tian and Max Zinter and H. Akbaba and P. Obeid and E. Chiocca and R. Weissleder and A. G. Kantarci and B. Tannous},
  journal={ACS nano},
  year={2019},
  volume={13 4},
  pages={
          4028-4040
        }
}
Targeted therapy against the programmed cell death ligand-1 (PD-L1) blockade holds considerable promise for the treatment of different tumor types; however, little effect has been observed against gliomas thus far. Effective glioma therapy requires a delivery vehicle that can reach tumor cells in the central nervous system, with limited systemic side effect. In this study, we developed a cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs… Expand
Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment
TLDR
Some nanoparticle (NP)-based therapeutics attached to GB cells with antigens and membrane receptors for site-directed drug targeting and multicore drug delivery systems are summarized, which could have better therapeutic potential for GB as well as efficient drug delivery reaching the tumor milieu. Expand
Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy
TLDR
Inspired by the capacity of natural proteins and viral particulates to cross the BBB, a synthetic protein nanoparticle (SPNP) based on polymerized human serum albumin (HSA) equipped with the cell-penetrating peptide iRGD is engineered and results in tumor regression and long-term survival in 87.5% of GBM-bearing mice. Expand
Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1/PD-L1 based immune checkpoint blockade in glioblastoma.
TLDR
The advances both in peptide-modified nano targeted drug delivery system and PD-1/PD-L1 based ICB treatment are reviewed, and a new strategy combining the two methods is proposed, which may provide a novel approach for GBM treatment. Expand
Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy
TLDR
Inspired by the capacity of natural proteins and viral particulates to cross the BBB, a synthetic protein nanoparticle (SPNP) based on polymerized human serum albumin (HSA) equipped with the cell-penetrating peptide iRGD is engineered and results in tumor regression and long-term survival in 87.5% of GBM bearing mice and prime the immune system to develop anti-GBM immunological memory. Expand
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
TLDR
The iRGD-mediated nano-carrier system could serve as a promising strategy in drug delivery to the deeper tumor regions, and be combined with various therapeutic interventions due to its novel targeting ability. Expand
Nanoparticle-mediated therapeutic compounds delivery to glioblastoma
TLDR
A more successful design of nanocarriers for efficient BBB crossing and delivery of diagnostic and/or therapeutic molecules to CNS will be needed to achieve efficient nanomedicine-based therapeutics for glioblastoma. Expand
Nano-Therapies for Glioblastoma Treatment
TLDR
Nano-drugs could help to improve the situation by enabling an increase of anti-glioblastoma multiforme (GBM) activity of chemo/gene therapeutic drugs, notably by an improved diffusion of these drugs through the blood brain barrier (BBB). Expand
The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy.
TLDR
The use of cascade chemo-photodynamic therapy with reactive oxygen species (ROS)-sensitive lipid-polymer hybrid nanoparticles TKHNP-C/D to potentiate the antitumor efficacy of anti-PD-L1 antibody to generate an abscopal effect which could simultaneously inhibit primary and distant tumor growth. Expand
X-rays-optimized delivery of radiolabeled albumin for cancer theranostics.
TLDR
Taking advantage of the increased expression of Caveolin-1 and the induced thrombosis under X-rays exposure, the delivery of radiolabeled HSA is optimized via enhancing the cell uptake and prolonging tumor retention of HSA for cancer combination therapy to guide the clinical albumin based combination therapy. Expand
A transformable gold nanocluster aggregate-based synergistic strategy for potentiated radiation/gene cancer therapy.
TLDR
The size transformation capability realized the high tumor retention/penetration and renal metabolism of AuNC-ASON in vivo and boosted the radio-susceptibility of cancer cells with the assistance of survivin gene interference, synergistically achieving potentiated tumor radiation/gene therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
TLDR
It is shown that the tumor microenvironment itself can be therapeutically primed to facilitate accumulation of multiple clinically relevant TNPs, and it is demonstrated that local tumor irradiation substantially increases TAM relative to tumor cells and, thus, TNP delivery. Expand
Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system.
TLDR
The results demonstrated that LNP is a kind of efficient CPPs especially for BBB-crossing application, and DGL-PEG-LNP/DNA is a potential non-viral platform for glioma gene therapy via intravenous administration. Expand
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
TLDR
Simultaneous imaging of intratumoral TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Expand
iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy
TLDR
iRGD enhanced transduction and early adenovirus dissemination through the tumor mass leading to an improved antitumor efficacy in tumors, however, iRGD did not change the normal organ transduction pattern. Expand
PD-1 blockade enhances the vaccination-induced immune response in glioma.
TLDR
Findings strongly suggest that the PD-1/PD-L1 pathway plays an important role in the adaptive immune resistance of established GBM in response to antitumor active vaccination and provide a rationale for the clinical translation of this combination therapy. Expand
Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis.
TLDR
The dual-ligand nanoparticle was capable of capturing different metastatic sites within the same animal that overexpressed either receptor or both of them, and the highly efficient targeting resulted in 22% of the injected dual- ligand nanoparticles being deposited in early-stage metastases within 2 h after injection. Expand
Tumor penetrating peptides for improved drug delivery
  • E. Ruoslahti
  • Biology, Medicine
  • Advanced drug delivery reviews
  • 2017
TLDR
Targeted delivery with tumor‐penetrating peptides has been shown to specifically increase the accumulation of drugs, antibodies and nanotherapeutics in experimental tumors in vivo, and in human tumors ex vivo. Expand
A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
TLDR
By targeting dispersed GBM cells and reducing MMP-2 activity, the combined use of CTX-nanovectors with radiotherapy may represent a promising therapeutic approach toward GBM. Expand
Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer
TLDR
It is shown that gold nanocluster-assisted delivery of siRNA of NGF (GNC–siRNA) allows efficient NGF gene silencing and pancreatic cancer treatment, and effectively inhibits the tumour progression in three pancreatic tumour models without adverse effects. Expand
Glioblastoma targeted therapy: updated approaches from recent biological insights
TLDR
The most promising biological insights that have opened the way for the development of targeted therapies in glioblastoma are reviewed, and recent data from clinical trials evaluating targeted therapies and immunotherapies are examined. Expand
...
1
2
3
4
5
...